Invida Goes Deeper In Skincare, Teams With Sinclair To Expand In Asia Pacific
This article was originally published in PharmAsia News
Executive Summary
UK specialty drug maker Sinclair signed a collaborative deal Dec. 7 with Singapore-based Invida to commercialize a number of dermatology products in 11 Asian markets. While multinational drug makers are accelerating expansion in Asia, specialty pharmaceutical companies are teaming up with contract sales firms such as Invida to capitalize on increasing demand in the region
You may also be interested in...
Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 2 of 2)
On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.
Invida CEO John Graham On Commercializing Products In Asia: An Interview With PharmAsia News (Part 1 of 2)
On the sidelines of the JP Morgan Healthcare Conference, Graham talks about Menarini’s acquisition of Invida, plans for expansion in China and India, and his favorite non-BRIC emerging markets.
Asia Beckons: Italy’s Menarini Wins Invida To Maximize Local Identity
Menarini is attracted to Invida for its speedy growth at the back of its Asia presence. Asia-Pacific region represents 10% of the world’s pharmaceutical market with a projected near-term 20% annual growth rate.